A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis

A Phase 4 Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis

The primary objective is to demonstrate added benefit of brodalumab versus a selected systemic comparator in treatment of moderate to severe plaque psoriasis in Germany in subjects who have not previously received systemic treatment for psoriasis. > Fumaric acid esters have been selected as the comparator because it is an established systemic treatment of psoriasis in Germany.>

Study Overview

• Status: Completed
• Conditions: Psoriasis Vulgaris
• Intervention / Treatment: Biological: Brodalumab; Drug: Fumaric acid esters

Detailed Description

A 24-week, randomised, open-label, active-controlled, parallel group, multi-centre trial with investigator-blinded efficacy assessments

• Study Type: Interventional
• Enrollment (Actual): 210
• Phase: Phase 4

Contacts and Locations

Study Locations

• Germany
  • Bad Bentheim, Germany, 48455
    • Fachklinik Bad Bentheim Klinik für Dermatologie
  • Berlin, Germany, 10117
    • Charité - Universitätsmedizin Berlin Klinik für Dermatologie, Venerologie und Allergologie Psoriasis Studien Zentrum
  • Berlin, Germany, 10783
    • Rothhaar Studien GmbH Dermatologisches Studienzentrum
  • Berlin, Germany, 13055
    • Hautarztpraxis Dr. Wildfeuer
  • Bielefeld, Germany, 33647
    • Klinikum Bielefeld Klinik für Dermatologie und Allergologie
  • Bochum, Germany, 44791
    • Hauttumorzentrum Ruhr- Universität im St. Josef Hospital
  • Bochum, Germany, 44793
    • Hautarztpraxis Dr. Niesmann und Dr. Othlinghaus
  • Bonn, Germany, 53127
    • Universitätsklinikum Bonn (AöR) Klinik und Poliklinik für Dermatologie und Allergologie
  • Buxtehude, Germany, 21614
    • Elbe Klinikum Buxtehude Klinik für Dermatologie
  • Darmstadt, Germany, 64283
    • Rosenpark Research
  • Dresden, Germany, 01307
    • Universitätsklinikum Carl Gustav Carus Klinik und Poliklinik für Dermatologie
  • Erlangen, Germany, 91054
    • Universitatsklinikum Erlangen Hautklinik
  • Frankfurt, Germany, 60590
    • Universitätsklinikum Frankfurt Klinik für Dermatologie
  • Friedrichshafen, Germany, 88045
    • Derma-Study-Center-Friedrichshafen
  • Gelsenkirchen, Germany, 45883
    • Gemeinschaftspraxis Rotterdam & Kollegen Facharzt für Haut & Geschlechtskrankheiten
  • Hamburg, Germany, 20246
    • Universitätsklinikum Hamburg-Eppendorf, Institut für Versorgungsforschung in der Dermatologie und bei Pflegeberufen
  • Hamburg, Germany, 20354
    • SCIderm GmbH
  • Hannover, Germany, 30625
    • Medizinische Hochschule Hannover Klinik für Dermatologie Allergologie und Venerologie
  • Heidelberg, Germany, 69120
    • Universitäts-Hautklinik Heidelberg
  • Kiel, Germany, 24105
    • Klinik für Dermatologie, Venerologie und Allergologie Universitätsklinikum Schleswig-Holstein, Campus Kiel Psoriasis-Zentrum
  • Lübeck, Germany, 23538
    • Exellenzzentrum Entzündungsmedizin (CCIM) Universitätsklinikum Schleswig-Holstein, Campus Lübeck
  • Mainz, Germany, 55131
    • University Medical Center Mainz Department of Dermatology and Allergy, Clinical Research Center
  • Mannheim, Germany, 68167
    • Universitätsklinikum Mannheim der Universität Heidelberg Klinik für Dermatologie, Venerologie und Allergologie
  • München, Germany, 80802
    • Technische Universität München Klinik und Poliklinik für Dermatologie und Allergologie
  • Osnabrück, Germany, 49074
    • Klinische Forschung Osnabrück - Klifos
  • Recklinghausen, Germany, 45657
    • KLINIKUM VEST GmbH Knappschaftskrankenhaus Recklinghausen Klinik für Dermatologie und Allergologie
  • Schweinfurt, Germany, 97421
    • Gemeinschaftspraxis Weber & Crainic
  • Stuttgart, Germany, 70178
    • Hautarztpraxis Dres. Leitz
  • Tübingen, Germany, 72076
    • University Medical Center University of Tübingen
  • Witten, Germany, 58453
    • Hautarztpraxis

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Main Criteria for Inclusion:>

• Men or women ≥18 years of age at the time of screening.>
• Subjects with chronic plaque type psoriasis diagnosed at least 6 months before randomisation.>
• Subjects with moderate to severe plaque psoriasis in whom topical therapy is not adequate and who are candidates for systemic therapy, defined at randomisation by PASI >10, affected BSA >10%, and DLQI >10.>
• Subject has no known history of active tuberculosis.>
• Subject has a negative test for tuberculosis taken at screening (negative Quantiferon test).>
• Subject and/or subject's designee is/are capable of administering subcutaneous injections.>

Main Criteria for Exclusion:>

• Previous or current systemic treatment of plaque psoriasis or known contraindication for systemic therapy.>
• Previous or current PUVA (psoralens and ultraviolet A) therapy.>

• Washouts and non-permitted drugs:>

  1. Have received phototherapy (UVA light therapy without psoralens, UVB light therapy, excimer laser, tanning beds etc. within 4 weeks of baseline, or>
  2. Have had topical psoriasis treatment within 2 weeks of baseline (exceptions: bland emollients without urea or beta or alpha hydroxy acids)>
  3. Have received any biologic immune modulating treatments used for indication other than psoriasis within 4 weeks of baseline or within a period of 5 half-lives of the IMP, whichever is longer>
  4. Have received any other systemic immune modulating treatment (including but not limited to oral retinoids, methotrexate, calcineurin inhibitors, oral or parenteral corticosteroids etc. used for indications other than psoriasis) within 4 weeks of baseline or within a period of 5 half-lives of the IMP, whichever is longer.>

• Subjects with any of the following laboratory abnormalities at screening:>

  1. Leukocyte cell count below 3×10^9/L or lymphocyte count below 0.7×10^9/L>
  2. Aspartate aminotransferase (AST) or alanine transferase (ALT) > 2× ULN (upper level of normal limit)>
  3. Absolute neutrophil count < 2×10^9/L>
  4. Serum creatinine > ULN.>
• History of depressive disorder within the last 2 years including current antidepressive treatment.>
• Subjects with a history of suicidal behaviour (suicide attempt). >
• Any suicidal ideation of severity 4 or 5 based on the eC-SSRS questionnaire at screening.>
• A PHQ-8 score of ≥10 corresponding to moderate to severe depression at screening.>

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Brodalumab; Kyntheum® (brodalumab)> pre-filled syringe 210 mg/1.5 mL solution for subcutaneous injections.> First 3 injections are administered weekly, and hereafter every two weeks (Q2W).	Biological: Brodalumab; Brodalumab is a recombinant fully human monoclonal immunoglobulin IgG2-antibody that binds with high affinity to human interleukin 17 receptor A (IL-17RA).> Blocking IL-17RA inhibits IL-17 cytokine-induced responses and results in reduced or normalised inflammation of the skin in subjects with psoriasis.; Other Names: Kyntheum®
Active Comparator: Fumaric acid esters; Fumaderm® initial dose tablets (30 mg dimethyl fumarate, 67 mg ethyl hydrogen fumarate calcium salt, 5 mg ethyl hydrogen fumarate magnesium salt, 3 mg ethyl hydrogen fumarate zinc salt)> Fumaderm® tablets (120 mg dimethyl fumarate, 87 mg ethyl hydrogen fumarate calcium salt, 5 mg ethyl hydrogen fumarate magnesium salt, 3 mg ethyl hydrogen fumarate zinc salt)> > Fumaderm® tablets are administered orally up to 3 times daily in accordance with the dosing scheme in the label.	Drug: Fumaric acid esters; Fumaric acid esters have been used to treat psoriasis since 1959. Systemic therapy with fumaric acid esters is based on an established dosing scheme with a gradual increase to improve tolerability, especially with regards to gastrointestinal side effects.; Other Names: Fumaderm®

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Having Least 75% Lower Psoriasis Area and Severity Index (PASI) Score Relative to Baseline (PASI 75 Response) From Baseline at Week 24	The PASI score grades the extent and severity of psoriatic involvement for each of four body regions (head and neck, upper extremities, trunk, and lower extremities) using a 7-point scale for extent of involvement in each body region and 5-point scales for severity of each of the clinical signs redness, thickness, and scalliness in each body region. Psoriasis Area and Severity Index is a scale ranging from 0 (no disease) to 72 (maximal disease).	Baseline to Week 24
Static Physician's Global Assessment (sPGA) Scale Score of 0 or 1 at Week 24	sPGA is a 6-point scale that represents the average lesion severity on the trunk and limbs. The assessment is based on the condition of the disease at the time of evaluation. Static Physician's Global Assessment is a scale ranging rom 0 (clear skin) to 5 (severe disease).	Baseline to Week 24

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Having Least 90% Lower Psoriasis Area and Severity Index (PASI) Score Relative to Baseline (PASI 90 Response) From Baseline at Week 24	The PASI score grades the extent and severity of psoriatic involvement for each of four body regions (head and neck, upper extremities, trunk, and lower extremities) using a 7-point scale for extent of involvement in each body region and 5-point scales for severity of each of the clinical signs redness, thickness, and scalliness in each body region. Psoriasis Area and Severity Index is a scale ranging from 0 (no disease) to 72 (maximal disease).	Baseline to Week 24
Having 100% Lower Psoriasis Area and Severity Index (PASI) Score Relative to Baseline (PASI 100 Response) From Baseline at Week 24	The PASI score grades the extent and severity of psoriatic involvement for each of four body regions (head and neck, upper extremities, trunk, and lower extremities) using a 7-point scale for extent of involvement in each body region and 5-point scales for severity of each of the clinical signs redness, thickness, and scalliness in each body region. Psoriasis Area and Severity Index is a scale ranging from 0 (no disease) to 72 (maximal disease).	Baseline to Week 24
Change From Baseline at Week 24 in PASI Score	The PASI score grades the extent and severity of psoriatic involvement for each of four body regions (head and neck, upper extremities, trunk, and lower extremities) using a 7-point scale for extent of involvement in each body region and 5-point scales for severity of each of the clinical signs redness, thickness, and scalliness in each body region. Psoriasis Area and Severity Index is a scale ranging from 0 (no disease) to 72 (maximal disease). A negative change in PASI score means that the PASI score was lower at the time of data collection.	Baseline to Week 24
Percent Change From Baseline in PASI Score at Week 24	The PASI score grades the extent and severity of psoriatic involvement for each of four body regions (head and neck, upper extremities, trunk, and lower extremities) using a 7-point scale for extent of involvement in each body region and 5-point scales for severity of each of the clinical signs redness, thickness, and scalliness in each body region. Psoriasis Area and Severity Index is a scale ranging from 0 (no disease) to 72 (maximal disease). A negative value in the percent change from baseline that the PASI score was lower at the time of data collection.	Baseline to Week 24
Change From Baseline at Week 24 in Affected Body Surface Area (BSA)	The surface area of the participant's hand (palm and fingers) is used as a reference measurement to calculate the percentage of each body region that is affected by psoriasis. One hand is approximately equal to 1% total BSA. Furthermore, the complete body surface area (BSA=100%) can be divided into regions that approximates percentages of BSA as follows: head and neck (10%), upper extremities (20%), the trunk including the axillae and groin (30%), and finally the lower extremities, including the buttocks (40%). A negative value in the percent change from baseline that the affected BSA was lower at the time of data collection.	Baseline to Week 24
Psoriasis Symptom Inventory (PSI) Responder at Week 24 (Total Score ≤ 8, With no Item Scores > 1)	The PSI consists of eight psoriasis-specific questions. Trial participants rated the severity of their symptoms in the last 24 hours from 'not at all' to 'very severe,' ranging from 0 to 4. Total scores range from 0 to 32 with higher scores indicating worse symptoms. PSI response is defined as total score ≤8 and no item score >1. Symptom-free day is defined as having daily total PSI of 0 on that day.	Week 24
PSI Total Score of 0 at Week 24	The PSI consists of eight psoriasis-specific questions. Trial participants rated the severity of their symptoms in the last 24 hours from 'not at all' to 'very severe,' ranging from 0 to 4. Total scores range from 0 to 32 with higher scores indicating worse symptoms. PSI response is defined as total score ≤8 and no item score >1. Symptom-free day is defined as having daily total PSI of 0 on that day.	Week 24
Number of Symptom-free Days From Randomisation to Week 24	The PSI consists of eight psoriasis-specific questions. Trial participants rated the severity of their symptoms in the last 24 hours from 'not at all' to 'very severe,' ranging from 0 to 4. Total scores range from 0 to 32 with higher scores indicating worse symptoms. PSI response is defined as total score ≤8 and no item score >1. Symptom-free day is defined as having daily total PSI of 0 on that day.	Baseline to Week 24
Burden of Symptoms	Burden of symptoms was assessed as the normalised area under the curve (AUC) of PSI from baseline to the last available assessment. The AUC for the PSI total score was calculated for each participant using the standard trapezoidal rule. The AUC was normalised by dividing it with the time from baseline to the last available assessment of the PSI total score. The PSI consists of eight psoriasis-specific questions. Trial participants rated the severity of their symptoms in the last 24 hours from 'not at all' to 'very severe,' ranging from 0 to 4. Total scores range from 0 to 32 with higher scores indicating worse symptoms.	Baseline to Week 24
Change From Baseline at Week 24 in Dermatology Life Quality Index (DLQI) Total Score	DLQI consists of 10 items addressing the participant's perception of the impact of their skin disease on different aspects of their quality of life over the last week such as dermatology-related symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the treatment. Each item is scored on a 4 point Likert scale (0 = not at all ⁄not relevant; 1 = a little; 2 = a lot; 3 = very much). The total score is the sum of the 10 items (0 to 30); a high score is indicative of a poor QoL.	Baseline to Week 24
DLQI Total Score of 0 or 1 at Week 24	DLQI consists of 10 items addressing the participant's perception of the impact of their skin disease on different aspects of their QoL over the last week such as dermatology-related symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the treatment. Each item is scored on a 4 point Likert scale (0 = not at all ⁄not relevant; 1 = a little; 2 = a lot; 3 = very much). The total score is the sum of the 10 items (0 to 30); a high score is indicative of a poor QoL.	Week 24

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline at Week 24 in NAPSI Total Score	The Nail Psoriasis Severity Index (NAPSI) grades nails by first dividing the nail area with imaginary horizontal and vertical lines into 4 quarters. The following 8 clinical features of nail psoriasis are then scored based on the number of quarters in which the feature is present (0 to 4) to arrive at a NAPSI score of 0 to 32 for each nail: Pitting.; Leukonychia.; Red spots in lunula.; Nail plate crumbling.; Oil drop (salmon patch) discoloration.; Onycholysis.; Nail bed hyperkeratosis.; Splinter haemorrhages. A negative change in NAPSI score means that the NAPSI score was lower at the time of data collection.	Baseline to Week 24

Collaborators and Investigators

• Sponsor: LEO Pharma

Study record dates

Study Major Dates

• Study Start (Actual): November 3, 2017
• Primary Completion (Actual): January 24, 2019
• Study Completion (Actual): March 21, 2019

Study Registration Dates

• First Submitted: November 1, 2017
• First Submitted That Met QC Criteria: November 1, 2017
• First Posted (Actual): November 6, 2017

Study Record Updates

• Last Update Posted (Actual): February 19, 2020
• Last Update Submitted That Met QC Criteria: February 10, 2020
• Last Verified: February 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Skin Diseases, Papulosquamous; Psoriasis; Dermatologic Agents; Brodalumab
• Other Study ID Numbers: LP0160-1327; 2016-003867-21 (EudraCT Number)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes